RBC Life Sciences, Inc (RBCL) Fair Value & Analysis
Consumer Defensive · US · Market cap $1.5K
RBC Life Sciences, Inc
RBCL · US
Fair value as of: Jun 26, 2026
From 6 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $17.72 to $0.0007 (−100.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.6000 · the $0.0007 price screens below the $0.0007 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
RBC Life Sciences, Inc (RBCL) currently trades at $0.0007, while our model-based Fair Value estimate is $0.0007 — implying the stock looks roughly 0.1% undervalued today. We read business quality at 55/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, RBC Life Sciences, Inc generated revenue of $24.1M at a net margin of -2.3%. Revenue declined 28.1% year over year. It earns a return on equity of -6.8%. The balance sheet holds a net cash position of $1.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
RBC Life Sciences, Inc. manufactures, markets, and distributes nutritional supplements and personal care products. The company offers wellness products, weight loss, sports, and fitness products. RBC Life Sciences, Inc. is headquartered in Irving, Texas.
Revenue & earnings trend
FY2012 – FY2016 · reported fiscal years
RBC Life Sciences, Inc reported revenue of $25.8M in FY2016 versus $25.2M in FY2012, a compound +0.6%/yr. Reported net income was −$756K in FY2016.
Is RBCL fairly valued? → Check now
Similar stocks
6 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | 2,590 MXN | 1,415 MXN | -45% |
| L'Oréal S.A LRLCF | $428.02 | $273.79 | -36% |
| Unilever PLC UNLYF | $59.34 | $46.11 | -22% |
| Colgate-Palmolive Company CPA | €77.58 | €35.72 | -54% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,122 | ₹677.55 | -68% |
| Reckitt Benckiser Group RBGLY | $12.32 | $17.37 | +41% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is RBC Life Sciences, Inc (RBCL) undervalued?
What is the fair value of RBCL?
What is the quality score of RBCL?
What is the revenue of RBC Life Sciences, Inc (RBCL)?
What is the net profit margin of RBCL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.